ArticleScientific reports2025
Luteolin targets MKK4 to attenuate particulate matter-induced MMP-1 and inflammation in human keratinocytes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Luteolin in osteoarticular diseases: a review of preclinical studies and translational perspectives.Inflammopharmacology · 2026Review
- IGFBP3 repression driven by inflammation links air pollution to placental and developmental defects.EMBO molecular medicine · 2026Article
- Unveiling the Skin Anti-Aging Potential of the NovelInternational journal of molecular sciences · 2025Article
- Genistein Inhibits Fine-Dust-Induced Matrix Metalloproteinase-1 in Human Keratinocytes.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Particulate matter (PM) is an environmental pollutant that causes premature skin aging and inflammation. In the present study, we investigated the protective effects of luteolin, a bioactive flavonoid, against PM-induced skin damage in human keratinocytes (HaCaT cells). We examined the antioxidant and anti-inflammatory properties of luteolin, focusing on its ability to inhibit key markers of skin aging and inflammation, specifically matrix metalloproteinase-1 (MMP-1) and cyclooxygenase-2 (COX-2). The results demonstrated that luteolin effectively suppressed PM-induced MMP-1 and COX-2 expression and reduced the production of the proinflammatory cytokine IL-6. Mechanistically, luteolin inhibited the activation of AP-1 and NF-κB pathways and decreased reactive oxygen species (ROS) levels in HaCaT cells. Additionally, luteolin binds directly to mitogen-activated protein kinase kinase (MKK) 4, inhibiting its kinase activity and subsequently reducing the phosphorylation of JNK1/2 and p38 mitogen-activated protein kinase. These findings suggest that luteolin can mitigate PM-induced skin aging and inflammation through multiple molecular pathways, highlighting its potential as a therapeutic agent to protect skin health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.